← Back to Search

Risk Disclosure Impact for Alzheimer's Disease (WeSHARE Trial)

N/A
Waitlist Available
Led By Sarah Hartz, MD
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant has genetic research results available including APOE status
Participant has had brain MRI and/or PET amyloid scan within the last 24 months or has plasma amyloid results
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months post-disclosure of risk estimate
Awards & highlights

WeSHARE Trial Summary

This trial will evaluate the psychological impact of receiving test results that estimate the risk of developing Alzheimer's disease dementia.

Who is the study for?
This trial is for healthy individuals aged 65 or older who are part of the Knight Alzheimer Disease Research Center and have been deemed cognitively normal. They must have recent brain scans or blood tests, genetic research results including APOE status, and be open to being contacted for further research.Check my eligibility
What is being tested?
The study examines the effects of sharing a five-year risk estimate for developing Alzheimer's disease dementia with participants who currently show no memory or thinking problems in various study arms (Arm A, B, C & D).See study design
What are the potential side effects?
Since this trial involves returning personal health risk information rather than medical treatments, traditional physical side effects are not applicable. However, receiving such information may have psychological impacts.

WeSHARE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have my genetic test results, including my APOE status.
Select...
I've had a brain MRI, PET amyloid scan, or plasma amyloid test in the last 2 years.
Select...
I am 65 years old or older.
Select...
I am a current participant of the Knight ADRC and had my clinical assessment last month.

WeSHARE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months post-disclosure of risk estimate
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months post-disclosure of risk estimate for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Impact of Events Scale (IES)

WeSHARE Trial Design

4Treatment groups
Active Control
Group I: Arm AActive Control1 Intervention
Participants randomized to Arm A will receive their research results two weeks after they review educational materials provided by the study and sign the informed consent document. Arm A is a neuroimaging arm.
Group II: Arm BActive Control1 Intervention
Participants randomized to Arm B will receive their research results one year after they review the educational materials provided by the study and sign the informed consent document. Arm B is a neuroimaging arm.
Group III: Arm CActive Control1 Intervention
Participants randomized to Arm C will receive their research results two weeks after they review educational materials provided by the study and sign the informed consent document. Arm C is a plasma amyloid arm.
Group IV: Arm DActive Control1 Intervention
Participants randomized to Arm D will receive their research results one year after they review the educational materials provided by the study and sign the informed consent document. Arm D is a plasma amyloid arm.

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,931 Previous Clinical Trials
2,299,259 Total Patients Enrolled
Sarah Hartz, MDPrincipal InvestigatorWashington University School of Medicine

Media Library

Arm A Clinical Trial Eligibility Overview. Trial Name: NCT04699786 — N/A
Alzheimer's Dementia Research Study Groups: Arm A, Arm B, Arm C, Arm D
Alzheimer's Dementia Clinical Trial 2023: Arm A Highlights & Side Effects. Trial Name: NCT04699786 — N/A
Arm A 2023 Treatment Timeline for Medical Study. Trial Name: NCT04699786 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities for participants to join the experiment?

"As indicated on clinicaltrials.gov, the medical trial posted on February 19th 2021 is no longer seeking candidates. However, there are currently 771 other studies actively looking for volunteers to participate in research activities."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies
2021. "Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04699786.
All > Alzheimer Disease > Alzheimers Disease
~86 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top